LATEST
Intelligent Protection Management agreed to acquire AdTech ITnewJanel agreed to acquire EnCor BiotechnologyNightfood Holdings acquired Jun Long Machine IndustrialClimb Global Solutions acquired NeoVADValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range Intermediate
Open App
Agreement signedPublished 28 Feb 2022

Biocon Biologics Limited /
Viatris Inc.

Biocon Biologics to acquire Viatris biosimilars portfolio

Price
$3.335bn
Stage
Agreement signed
Source · 28 Feb 2022
See the source
01 / BuyerBiocon Biologics Limited
02 / TargetViatris Inc.
01

What happened

Biocon Biologics Limited agreed to acquire Viatris Inc.’s biosimilars portfolio under a Transaction Agreement entered into on Feb. 27, 2022.

The consideration is up to $3.335 billion on a cash-free, debt-free basis, including cash, preferred equity and future cash payments.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Biocon Biologics to acquire Viatris biosimilars portfolio

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Agreement signed

    The source this page is built from.

  2. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.